Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.

Cold Spring Harbor molecular case studies - 1 Apr 2018

Owen Daniel R, Wong Hui-Li, Bonakdar Melika, Jones Martin, Hughes Christopher S, Morin Gregg B, Jones Steven J M, Renouf Daniel J, Lim Howard, Laskin Janessa, Marra Marco, Yip Stephen, Schaeffer David F

Abstract excerpt

ERBB2 amplification has been identified in ∼5% of KRAS wild-type colorectal cancers (CRCs). A recent clinical trial showed response to HER2-directed therapy in a subset of ERBB2-amplified metastatic CRCs resistant to chemotherapy and EGFR-directed therapy. With the aim of better understanding mechanisms of resistance to HER2-directed and EGFR-directed therapies, we report the complete molecular characterization...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Gene Amplification

Share to Molecular Targeted Therapy

Share to Receptor, ErbB-2

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 29438965
DOI: 10.1101/mcs.a002535
PMCID: PMC5880263

Genes

ERBB2
EGFR
KRAS
MET
MUC1
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.PMID 29438965Read ↗

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Semantic proximity Read ↗

HER2 targeted therapy in colorectal cancer: New horizons.Semantic proximity Read ↗

Genomic landscape and clinical characteristics of ERBB2/HER2-mutated colorectal cancers.Semantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic SchemesSemantic proximity Read ↗

ERBB2 emerges as a new target for colorectal cancer.Semantic proximity Read ↗

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.Semantic proximity Read ↗

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.Semantic proximity Read ↗

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical caseSemantic proximity Read ↗

Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer.Semantic proximity Read ↗

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.Semantic proximity Read ↗

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.